{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:49:08Z","timestamp":1791920948843,"version":"4.3.4"},"reference-count":187,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007957","name":"Chongqing Municipal Education Commission","doi-asserted-by":"publisher","award":["KJZD-K202501108"],"award-info":[{"award-number":["KJZD-K202501108"]}],"id":[{"id":"10.13039\/501100007957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007957","name":"Chongqing Municipal Education Commission","doi-asserted-by":"publisher","award":["KJZD-M202501106"],"award-info":[{"award-number":["KJZD-M202501106"]}],"id":[{"id":"10.13039\/501100007957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22307012"],"award-info":[{"award-number":["22307012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004867","name":"Chongqing University of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004867","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118501","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:17:14Z","timestamp":1791213434000},"page":"118501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P3","title":["Nucleoside antitumor drugs: From molecular mechanisms and adaptive resistance to clinical translation"],"prefix":"10.1016","volume":"254","author":[{"given":"Chunyuan","family":"Gan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingheng","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shili","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6395-9235","authenticated-orcid":false,"given":"Yaqin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bcp.2026.118501_b0005","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13046-025-03470-z","article-title":"Unraveling resistance mechanisms to the novel nucleoside analog RX-3117 in lung cancer: insights into DNA repair, cell cycle dysregulation and targeting PKMYT1 for improved therapy","volume":"44","author":"Vahabi","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2026.118501_b0015","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202500423R","article-title":"AP1M2 Drives Gemcitabine\u2010Cisplatin Chemoresistance by Enhancing RAD54B\u2010Associated DNA Repair in Bladder Cancer","volume":"39","author":"Liu","year":"2025","journal-title":"FASEB J."},{"issue":"7","key":"10.1016\/j.bcp.2026.118501_b0020","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/biology14070838","article-title":"Epigenetic Drivers of Chemoresistance in Nucleobase and Nucleoside Analog Therapies","volume":"14","author":"Kaszycki","year":"2025","journal-title":"Biology"},{"issue":"4","key":"10.1016\/j.bcp.2026.118501_b0025","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3390\/biom16040587","article-title":"Epigenetic Biomarkers for predicting Nucleoside Analog Drug Response and Resistance in Cancer","volume":"16","author":"Kaszycki","year":"2026","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2026.118501_b0035","doi-asserted-by":"crossref","first-page":"958","DOI":"10.7150\/ijbs.103877","article-title":"Exploring viral mimicry combined with epigenetics and tumor immunity: new perspectives in cancer therapy","volume":"21","author":"Wang","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bcp.2026.118501_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1173432","article-title":"Advanced prodrug strategies in nucleoside analogues targeting the treatment of gastrointestinal malignancies","volume":"11","author":"Xu","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2026.118501_b0045","article-title":"Advancing Epigenetic Combination Therapy in Oncology: Multifunctional Nano-Drug delivery Systems for Synergistic Efficacy and Precision Modulation","volume":"14853\u201314883","author":"Gao","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bcp.2026.118501_b0050","article-title":"The Role of SAMHD1 in Viral Resistance and Transduction Efficiency challenges in Pediatric Hematological Malignancies: Mechanistic Insights and Clinical Perspectives","author":"Alzamzami","year":"2025","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0055","first-page":"217","volume":"44","author":"M. Vahabi, G. Xu, D. Sarkisjan, B.E. Hassouni, G. Mantini, V. Donati, B. Wang, G. Lencioni, R.J. Honeywell, D.J.J.o.E. Deng, C.C. Research","year":"2025","journal-title":"Unraveling Resistance Mechanisms to the Novel Nucleoside Analog RX-3117 in Lung Cancer: Insights into DNA Repair, Cell Cycle Dysregulation and Targeting PKMYT1 for Improved Therapy."},{"key":"10.1016\/j.bcp.2026.118501_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2025.1706040","article-title":"Microbial metabolites in tumor metabolic reprogramming and immunotherapy: new insights","volume":"15","author":"Wang","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.bcp.2026.118501_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1510851","article-title":"Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer","volume":"15","author":"Xu","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118501_b0070","doi-asserted-by":"crossref","first-page":"12369","DOI":"10.1021\/acs.jmedchem.5c00826","article-title":"Current and emerging prodrug strategies","volume":"68","author":"Brown","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118501_b0075","article-title":"Prodrug-based drug delivery systems: strategic approaches and emerging challenges in targeted therapeutics","volume":"1\u201316","author":"Chaturvedi","year":"2025","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118501_b0080","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1021\/acs.jmedchem.7b00734","article-title":"The ProTide Prodrug Technology: from the Concept to the Clinic: Miniperspective","volume":"61","author":"Mehellou","year":"2017","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2026.118501_b0085","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s13318-022-00786-5","article-title":"Is monitoring of the intracellular active metabolite levels of nucleobase and nucleoside analogs ready for precision medicine applications?","volume":"47","author":"Huang","year":"2022","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.bcp.2026.118501_b0090","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1124\/dmd.122.000856","article-title":"Cell and tissue specific metabolism of nucleoside and nucleotide drugs: case studies and implications for precision medicine","volume":"51","author":"To","year":"2023","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0095","article-title":"Clinical translation of Self\u2010Assembled cancer nanomedicines","volume":"4","author":"Mi","year":"2021","journal-title":"Advanced Therapeutics."},{"issue":"5","key":"10.1016\/j.bcp.2026.118501_b0100","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1016\/j.apsb.2025.03.016","article-title":"Prodrug-based combinational nanomedicine remodels lipid metabolism for reinforced ferroptosis and immune activation","volume":"15","author":"Lin","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2026.118501_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115987","article-title":"Is it still worth renewing nucleoside anticancer drugs nowadays?","volume":"264","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118501_b0110","article-title":"A general nanoplatform for nucleotide drug delivery: from molecular binding to antiviral therapy","volume":"114245","author":"Zhou","year":"2025","journal-title":"J. Control. Release"},{"issue":"33","key":"10.1016\/j.bcp.2026.118501_b0115","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.2174\/1381612828666220608141049","article-title":"Application of artificial intelligence in drug discovery","volume":"28","author":"Chopra","year":"2022","journal-title":"Curr. Pharm. Des."},{"issue":"23","key":"10.1016\/j.bcp.2026.118501_b0120","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1021\/acs.chemrev.6b00209","article-title":"Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs","volume":"116","author":"Shelton","year":"2016","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-022-01263-x","article-title":"Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.118501_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115741","article-title":"Nucleoside-based anticancer drugs: Mechanism of action and drug resistance","volume":"215","author":"Hruba","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118501_b0135","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.trecan.2023.04.008","article-title":"Emerging roles of nucleotide metabolism in cancer","volume":"9","author":"Shi","year":"2023","journal-title":"Trends Cancer."},{"key":"10.1016\/j.bcp.2026.118501_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.fmre.2025.06.002","article-title":"Nucleosides with fluorinated nucleobases for antiviral and anticancer therapies","author":"Meng","year":"2025","journal-title":"Fundam. Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118501_b0145","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/cells15020130","article-title":"Enhancing the Nucleoside Analog Response with Translational Therapeutic Approaches to Overcome Resistance","volume":"15","author":"Thibodeau","year":"2026","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.bcp.2026.118501_b0150","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.118501_b0155","first-page":"1165","article-title":"Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells","volume":"34","author":"Song","year":"2009","journal-title":"Int. J. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118501_b0160","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s43018-024-00755-8","article-title":"APOBEC3 upregulation drives gemcitabine resistance","volume":"5","author":"Maciejowski","year":"2024","journal-title":"Nat Cancer."},{"issue":"11","key":"10.1016\/j.bcp.2026.118501_b0165","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/s41401-019-0227-7","article-title":"A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability","volume":"40","author":"Li","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2026.118501_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.106346","article-title":"Unlocking the potential of cytarabine: a comprehensive review from molecular insights to advanced nanoformulations and Co-delivery strategies for enhanced drug efficacy","volume":"102","author":"Shabestari","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118501_b0175","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1021\/acs.jproteome.4c00839","article-title":"Gemcitabine alters phosphatidylcholine metabolism in mouse pancreatic tumors","volume":"24","author":"Phulara","year":"2025","journal-title":"J. Proteome Res."},{"issue":"30","key":"10.1016\/j.bcp.2026.118501_b0180","doi-asserted-by":"crossref","first-page":"17480","DOI":"10.1039\/D5NR02005K","article-title":"Recent progress in gemcitabine-loaded nanoparticles for pancreatic cancer therapy: a review","volume":"17","author":"Li","year":"2025","journal-title":"Nanoscale"},{"key":"10.1016\/j.bcp.2026.118501_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1134895","article-title":"Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK\/T cell lymphoma cells","volume":"14","author":"Lin","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118501_b0190","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/cr900028p","article-title":"Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer","volume":"109","author":"Parker","year":"2009","journal-title":"Chem. Rev."},{"issue":"9","key":"10.1016\/j.bcp.2026.118501_b0195","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1158\/1541-7786.MCR-19-1051","article-title":"DNA replication stress induced by trifluridine determines tumor cell fate according to p53 status","volume":"18","author":"Kataoka","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2026.118501_b0200","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ctrv.2015.06.001","article-title":"TAS-102, a novel antitumor agent: a review of the mechanism of action","volume":"41","author":"Lenz","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2026.118501_b0205","article-title":"5-fluorouracil and other fluoropyrimidines in colorectal cancer","volume":"206","author":"Vodenkova","year":"2020","journal-title":"Past, Present and Future."},{"key":"10.1016\/j.bcp.2026.118501_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.117988","article-title":"Xianglian Pill combined with 5-fluorouracil enhances antitumor activity and reduces gastrointestinal toxicity in gastric cancer by regulating the p38 MAPK\/NF-\u03baB signaling pathway","volume":"326","author":"Yu","year":"2024","journal-title":"J. Ethnopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0215","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41467-021-27847-8","article-title":"Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance","volume":"13","author":"Therizols","year":"2022","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bcp.2026.118501_b0220","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3390\/biom12060815","article-title":"Inhibitors of the cancer target ribonucleotide reductase, past and present","volume":"12","author":"Huff","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2026.118501_b0225","article-title":"Preclinical Toxicology of Antimetabolite Drugs used in Cancer Therapy\u2013Literary Review","author":"Balaiyawala","year":"2024","journal-title":"Journal"},{"issue":"23","key":"10.1016\/j.bcp.2026.118501_b0230","doi-asserted-by":"crossref","first-page":"16903","DOI":"10.3390\/ijms242316903","article-title":"Cellular responses to widespread DNA replication stress","volume":"24","author":"Nickoloff","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.bcp.2026.118501_b0235","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1038\/sj.onc.1204341","article-title":"DNA methylation, methyltransferases, and cancer","volume":"20","author":"Robertson","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118501_b0240","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1072651","article-title":"Recent progress in DNA methyltransferase inhibitors as anticancer agents","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118501_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113098","article-title":"Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment","volume":"42","author":"Yabushita","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2026.118501_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.991751","article-title":"Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines; the impact of DCK overexpression","volume":"13","author":"Buocikova","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118501_b0255","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026948","article-title":"DNA hypomethylating drugs in cancer therapy","volume":"7","author":"Sato","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"33","key":"10.1016\/j.bcp.2026.118501_b0260","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1038\/s41388-022-02404-9","article-title":"DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.bcp.2026.118501_b0265","first-page":"14042","volume":"23","author":"Alexandraki","year":"2022","journal-title":"Decitabine Treatment Induces a Viral Mimicry Response in Cervical Cancer Cells and Further Sensitizes Cells to Chemotherapy."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0270","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41401-025-01639-y","article-title":"DNMT inhibition epigenetically restores the cGAS-STING pathway and activates RIG-I\/MDA5-MAVS to enhance antitumor immunity","volume":"47","author":"Tu","year":"2026","journal-title":"Acta Pharmacol. Sin."},{"issue":"12","key":"10.1016\/j.bcp.2026.118501_b0275","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/2159-8290.CD-25-0587","article-title":"Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by triggering Viral Mimicry in Relapsed\/Refractory NK\/T-cell Lymphoma","volume":"15","author":"Huang","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118501_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115741","article-title":"Nucleoside-based anticancer drugs: Mechanism of action and drug resistance","volume":"215","author":"Hruba","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"50","key":"10.1016\/j.bcp.2026.118501_b0285","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1038\/onc.2008.316","article-title":"Nucleoside analogs: molecular mechanisms signaling cell death","volume":"27","author":"Ewald","year":"2008","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bcp.2026.118501_b0290","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10070240","article-title":"Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism","volume":"10","author":"Tsesmetzis","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0295","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s43556-025-00352-w","article-title":"Drug resistance in cancer: molecular mechanisms and emerging treatment strategies","volume":"6","author":"Li","year":"2025","journal-title":"Mol Biomed."},{"key":"10.1016\/j.bcp.2026.118501_b0300","article-title":"Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118501_b0305","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3390\/pharmaceutics14081606","article-title":"Nanomedicines for overcoming cancer drug resistance","volume":"14","author":"Hu","year":"2022","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.bcp.2026.118501_b0310","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.12805","article-title":"Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy\u2010na\u00efve pT2 gallbladder adenocarcinoma patients","volume":"68","author":"Espinoza","year":"2016","journal-title":"Histopathology"},{"issue":"40","key":"10.1016\/j.bcp.2026.118501_b0315","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.3748\/wjg.v27.i40.6844","article-title":"Role of human nucleoside transporters in pancreatic cancer and chemoresistance","volume":"27","author":"Carter","year":"2021","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118501_b0320","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.3390\/cancers12113206","article-title":"\u201cOpen Sesame?\u201d: Biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity in the uptake and cytotoxicity of gemcitabine in pancreatic cancer","volume":"12","author":"Randazzo","year":"2020","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.bcp.2026.118501_b0325","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1158\/1078-0432.CCR-22-2576","article-title":"hENT1 expression predicts response to gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma","volume":"28","author":"Perera","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.bcp.2026.118501_b0330","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.3390\/ijms25137012","article-title":"Elucidation of the gemcitabine transporters of escherichia coli K-12 and gamma-proteobacteria linked to gemcitabine-related chemoresistance","volume":"25","author":"Iosifidou","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.bcp.2026.118501_b0335","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.3390\/cancers17162628","article-title":"Nanoparticle-based delivery strategies for combating drug resistance in cancer therapeutics","volume":"17","author":"Park","year":"2025","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.bcp.2026.118501_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118824","article-title":"MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells","volume":"1867","author":"Masetto","year":"2020","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0345","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/or.2023.8666","article-title":"Multidrug resistance protein 5 affects cell proliferation, migration and gemcitabine sensitivity in pancreatic cancer MIA Paca\u20112 and PANC\u20111 cells","volume":"51","author":"He","year":"2023","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2026.118501_b0350","volume":"13","author":"Zhang","year":"2025","journal-title":"Biology, Clinical Application and Drug Resistance Mechanism of Gemcitabine."},{"key":"10.1016\/j.bcp.2026.118501_b0355","article-title":"The role of various collagen types in tumor biology: a review","volume":"15","author":"Zhou","year":"2025","journal-title":"Front. Oncol."},{"issue":"50","key":"10.1016\/j.bcp.2026.118501_b0360","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202506926","article-title":"Collagen Signaling via DDR1 Exacerbates Barriers to Macromolecular Drug delivery in a 3D Model of Pancreatic Cancer Fibrosis","volume":"21","author":"Ohira","year":"2025","journal-title":"Small"},{"issue":"13","key":"10.1016\/j.bcp.2026.118501_b0365","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","article-title":"Decitabine\/cedazuridine: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0370","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","article-title":"Oral decitabine\u2013cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"Garcia-Manero","year":"2024","journal-title":"The Lancet Haematology."},{"issue":"16","key":"10.1016\/j.bcp.2026.118501_b0375","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1158\/1078-0432.CCR-21-4498","article-title":"FDA approval summary: decitabine and cedazuridine tablets for myelodysplastic syndromes","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118501_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.108907","article-title":"Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnel","volume":"27","author":"Zhang","year":"2024","journal-title":"iScience"},{"issue":"8","key":"10.1016\/j.bcp.2026.118501_b0385","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/15257770.2024.2325439","article-title":"The N-terminal SAM domain of the dNTPase SAMHD1 is not required for inhibition by small molecule TH6342","volume":"43","author":"Dirks","year":"2024","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"10","key":"10.1016\/j.bcp.2026.118501_b0390","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1021\/acschembio.3c00118","article-title":"Deoxyguanosine-Linked Bifunctional Inhibitor of SAMHD1 dNTPase activity and Nucleic Acid Binding","volume":"18","author":"Egleston","year":"2023","journal-title":"ACS Chem. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118501_b0395","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nm.4265","article-title":"Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies","volume":"23","author":"Herold","year":"2017","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0400","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41392-025-02523-1","article-title":"Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses","volume":"10","author":"Sun","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0405","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13596-024-00747-0","article-title":"Precision medicine engaging nucleoside analogues: New advances to a conventional arsenal","volume":"25","author":"Yehia","year":"2025","journal-title":"Adv. Tradit. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0410","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/s41467-017-01582-5","article-title":"Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology","volume":"8","author":"Hammam","year":"2017","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.bcp.2026.118501_b0415","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/15257770.2023.2272640","article-title":"Clinical use of biomarkers in the field of cytotoxic nucleoside analogues","volume":"43","author":"Jordheim","year":"2024","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"15_suppl","key":"10.1016\/j.bcp.2026.118501_b0420","doi-asserted-by":"crossref","first-page":"e13633","DOI":"10.1200\/jco.2010.28.15_suppl.e13633","article-title":"Epigenetic changes in nucleoside transporter hENT1 and dCK, as mechanism for gemcitabine-aquired resistance in cervical cancer cell lines","volume":"28","author":"Candelaria","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118501_b0425","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.3390\/ijms26115083","article-title":"Acquired Resistance to Decitabine Associated with the Deoxycytidine Kinase A180P Mutation: Implications for the Order of Hypomethylating Agents in Myeloid Malignancies Treatment","volume":"26","author":"Simonicova","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.118501_b0430","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nsb942","article-title":"Structure of human dCK suggests strategies to improve anticancer and antiviral therapy","volume":"10","author":"Sabini","year":"2003","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.bcp.2026.118501_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113742","article-title":"Development and preclinical pharmacology of a novel dCK inhibitor, DI-87","volume":"172","author":"Poddar","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0440","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-biochem-013118-111843","article-title":"Ribonucleotide reductases: structure, chemistry, and metabolism suggest new therapeutic targets","volume":"89","author":"Greene","year":"2020","journal-title":"Annu. Rev. Biochem"},{"issue":"16","key":"10.1016\/j.bcp.2026.118501_b0445","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/onc.2014.155","article-title":"Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies","volume":"34","author":"Aye","year":"2015","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bcp.2026.118501_b0450","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.neo.2021.05.007","article-title":"mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer","volume":"23","author":"Tian","year":"2021","journal-title":"Neoplasia"},{"issue":"16","key":"10.1016\/j.bcp.2026.118501_b0455","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164200","article-title":"Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment","volume":"13","author":"Bothou","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.bcp.2026.118501_b0460","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00280-023-04579-8","article-title":"Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients","volume":"92","author":"Abbaspour","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118501_b0465","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10637-024-01455-x","article-title":"Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery","volume":"42","author":"Silli","year":"2024","journal-title":"Invest. New Drugs"},{"issue":"3","key":"10.1016\/j.bcp.2026.118501_b0470","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/jm0496279","article-title":"Structure of human cytidine deaminase bound to a potent inhibitor","volume":"48","author":"Chung","year":"2005","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.118501_b0475","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ymthe.2019.11.026","article-title":"The Emerging Role of Cytidine Deaminase in Human Diseases: a New Opportunity for Therapy?","volume":"28","author":"Frances","year":"2020","journal-title":"Mol. Ther."},{"issue":"29","key":"10.1016\/j.bcp.2026.118501_b0480","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1038\/onc.2013.357","article-title":"Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase","volume":"33","author":"Weizman","year":"2014","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bcp.2026.118501_b0485","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1158\/0008-5472.CAN-22-3219","article-title":"Cytidine Deaminase Resolves Replicative stress and Protects Pancreatic Cancer from DNA-Targeting Drugs","volume":"84","author":"Lumeau","year":"2024","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118501_b0490","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41419-022-05023-0","article-title":"Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.118501_b0495","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1038\/ncomms3722","article-title":"Structural insight into dGTP-dependent activation of tetrameric SAMHD1 deoxynucleoside triphosphate triphosphohydrolase","volume":"4","author":"Zhu","year":"2013","journal-title":"Nat. Commun."},{"issue":"18","key":"10.1016\/j.bcp.2026.118501_b0500","doi-asserted-by":"crossref","first-page":"E1843","DOI":"10.1073\/pnas.1401706111","article-title":"GTP activator and dNTP substrates of HIV-1 restriction factor SAMHD1 generate a long-lived activated state","volume":"111","author":"Hansen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0505","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1038\/s41467-024-48237-w","article-title":"Platform-directed allostery and quaternary structure dynamics of SAMHD1 catalysis","volume":"15","author":"Acton","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bcp.2026.118501_b0510","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nm.4255","article-title":"SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia","volume":"23","author":"Schneider","year":"2017","journal-title":"Nat. Med."},{"issue":"43","key":"10.1016\/j.bcp.2026.118501_b0515","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1805593115","article-title":"The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1","volume":"115","author":"Knecht","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"21","key":"10.1016\/j.bcp.2026.118501_b0520","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1002\/1878-0261.13227","article-title":"Targeting the DNA damage response and repair in cancer through nucleotide metabolism","volume":"16","author":"Helleday","year":"2022","journal-title":"Mol. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118501_b0525","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nm.4265","article-title":"Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies","volume":"23","author":"Herold","year":"2017","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.bcp.2026.118501_b0530","article-title":"Mre11 exonuclease activity removes the chain-terminating nucleoside analog gemcitabine from the nascent strand during DNA replication","volume":"6","author":"B\u00f6ckemeier","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bcp.2026.118501_b0535","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2147\/DDDT.S462056","article-title":"Targeting WEE1 kinase in gynecological malignancies","author":"Zhang","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0540","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/cas.14718","article-title":"dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA\u2010repair\u2010defective human cancer cells","volume":"112","author":"Yokogawa","year":"2021","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0545","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/cimb48010067","article-title":"Replication stress in Cancer: Mechanistic Insights and Therapeutic Opportunities for Radiosensitization","volume":"48","author":"Vasilopoulos","year":"2026","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0550","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/biomedicines12010227","article-title":"Overcoming Microbiome-acquired gemcitabine resistance in pancreatic ductal adenocarcinoma","volume":"12","author":"Mendes","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2026.118501_b0555","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1091124","article-title":"Microbiota and their metabolites potentiate cancer immunotherapy: Therapeutic target or resource for small molecule drug discovery?","volume":"13","author":"Du","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0560","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13046-018-0985-y","article-title":"Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer","volume":"38","author":"Zhang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118501_b0565","article-title":"Fecal microbiota transplantation augments 5-fluorouracil efficacy in pancreatic cancer via gut microbiota modulation","volume":"16","author":"Li","year":"2025","journal-title":"Front. Microbiol."},{"issue":"12_Supplement","key":"10.1016\/j.bcp.2026.118501_b0570","doi-asserted-by":"crossref","first-page":"C032","DOI":"10.1158\/1535-7163.TARG-23-C032","article-title":"Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: phase 2 results from the NuTide: 701 study","volume":"22","author":"Blagden","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.bcp.2026.118501_b0575","doi-asserted-by":"crossref","first-page":"257","DOI":"10.20517\/cdr.2022.136","article-title":"Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects","volume":"6","author":"Gmeiner","year":"2023","journal-title":"Cancer Drug Resistance."},{"issue":"6","key":"10.1016\/j.bcp.2026.118501_b0580","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/1042819032000159861","article-title":"Problems related to resistance to cytarabine in acute myeloid leukemia","volume":"45","author":"Cros","year":"2004","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.bcp.2026.118501_b0585","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/1389450033490957","article-title":"Drug resistance to cytotoxic nucleoside analogues","volume":"4","author":"Jordheim","year":"2003","journal-title":"Curr. Drug Targets"},{"issue":"7","key":"10.1016\/j.bcp.2026.118501_b0590","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bcp.2026.118501_b0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2023.101521","article-title":"Mechanisms of resistance to hypomethylating agents and BCL-2 inhibitors","volume":"36","author":"Desai","year":"2023","journal-title":"Best Practice Research Clinical Haematology."},{"issue":"12","key":"10.1016\/j.bcp.2026.118501_b0600","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40262-021-01065-3","article-title":"Review of transporter substrate, inhibitor, and inducer characteristics of cladribine","volume":"60","author":"Hermann","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcp.2026.118501_b0605","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2026.1818501","article-title":"Cellular pharmacology of fludarabine: molecular determinants of transport and metabolism","volume":"17","author":"Mseddi","year":"2026","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118501_b0610","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41375-025-02529-2","article-title":"Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action","volume":"39","author":"Hormann","year":"2025","journal-title":"Leukemia"},{"issue":"29","key":"10.1016\/j.bcp.2026.118501_b0615","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v31.i29.109947","article-title":"Targeted therapy combined with immunotherapy vs trifluridine\/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer","volume":"31","author":"Gao","year":"2025","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118501_b0620","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3892\/or.2014.3487","article-title":"Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models","volume":"32","author":"Tanaka","year":"2014","journal-title":"Oncol. Rep."},{"issue":"18","key":"10.1016\/j.bcp.2026.118501_b0625","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118501_b0630","doi-asserted-by":"crossref","unstructured":"J. Taieb, M. Fakih, J. Tabernero, F. Ciardiello, E. Van Cutsem, G. Soler, E. Calleja, V. Barboux, L. Roby, N. Amellal, Impact of treatment with trifluridine\/tipiracil in combination with bevacizumab on health-related quality of life and performance status in refractory metastatic colorectal cancer: an analysis of the phase III SUNLIGHT trial, Clinical Colorectal Cancer. 24(2) (2025) 180-187. e4.","DOI":"10.1016\/j.clcc.2024.12.002"},{"issue":"12","key":"10.1016\/j.bcp.2026.118501_b0635","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/sj.bjc.6602881","article-title":"The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia","volume":"93","author":"Hubeek","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2026.118501_b0640","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40265-025-02194-w","article-title":"The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and Safety: L. Pagano et al","volume":"85","author":"Pagano","year":"2025","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.bcp.2026.118501_b0645","doi-asserted-by":"crossref","DOI":"10.1002\/cnr2.70199","article-title":"The Clinical Safety and Efficacy of Cytarabine and Daunorubicin Liposome (CPX\u2010351) in Acute Myeloid Leukemia patients: a Systematic Review","volume":"8","author":"Alzahrani","year":"2025","journal-title":"Cancer Reports."},{"key":"10.1016\/j.bcp.2026.118501_b0650","article-title":"CPX-351: from preclinical studies to future directions","volume":"102605","author":"Sperotto","year":"2026","journal-title":"Curr. Opin. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118501_b0655","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3390\/cancers13050966","article-title":"Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers","volume":"13","author":"Di Francia","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0660","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-021-01119-w","article-title":"Quality-adjusted Time without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7+ 3 in older adults with newly diagnosed high-risk\/secondary AML","volume":"14","author":"Cortes","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118501_b0665","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","article-title":"First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5: 1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia","volume":"29","author":"Feldman","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.bcp.2026.118501_b0670","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1182\/bloodadvances.2021006468","article-title":"Transplant outcomes after CPX-351 vs 7+ 3 in older adults with newly diagnosed high-risk and\/or secondary AML","volume":"6","author":"Uy","year":"2022","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.bcp.2026.118501_b0675","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1021\/jm401853a","article-title":"Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development","volume":"57","author":"Slusarczyk","year":"2014","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2026.118501_b0680","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1593\/neo.10576","article-title":"Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells","volume":"12","author":"Hagmann","year":"2010","journal-title":"Neoplasia"},{"issue":"12_Supplement","key":"10.1016\/j.bcp.2026.118501_b0685","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1538-7445.AM2022-1835","article-title":"NUC-3373 targets the DNA-directed pathway more effectively than 5-FU","volume":"82","author":"Bre","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118501_b0690","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1016\/j.annonc.2023.04.017","article-title":"O-2 phase III study of NUC-1031+ cisplatin vs gemcitabine+ cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide: 121)","volume":"34","author":"Knox","year":"2023","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118501_b0695","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jhep.2025.01.040","article-title":"A phase III randomized study of first-line NUC-1031\/cisplatin vs. gemcitabine\/cisplatin in advanced biliary tract cancer","volume":"83","author":"Knox","year":"2025","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118501_b0700","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12032-020-01386-6","article-title":"NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials","volume":"37","author":"Kapacee","year":"2020","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bcp.2026.118501_b0705","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.93","article-title":"A phase Ib study of NUC-3373 in combination with standard therapies in advanced\/metastatic colorectal cancer (NuTide: 302)","author":"Coveler","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.bcp.2026.118501_b0710","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1158\/1078-0432.CCR-21-1652","article-title":"The novel nucleoside analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human phase I clinical trial","volume":"27","author":"Schwenzer","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.bcp.2026.118501_b0715","first-page":"15789","volume":"65","author":"Serpi","year":"2022","journal-title":"Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3\u2032-Deoxyadenosine, as a Potential Anticancer Agent."},{"key":"10.1016\/j.bcp.2026.118501_b0720","doi-asserted-by":"crossref","first-page":"S745","DOI":"10.1016\/j.annonc.2022.07.584","article-title":"455MO NUC-7738 in patients with advanced solid tumours: phase I results from the NuTide: 701 phase I\/II study","volume":"33","author":"Symeonides","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.118501_b0725","doi-asserted-by":"crossref","first-page":"S917","DOI":"10.1016\/j.annonc.2025.08.2161","article-title":"1530P Patient derived organoids reveal synergy between NUC-7738 and PD-1 inhibition in renal cell carcer","volume":"36","author":"Abdullah","year":"2025","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118501_b0730","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113206","article-title":"\u201cOpen Sesame?\u201d: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer","volume":"12","author":"Randazzo","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bcp.2026.118501_b0735","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cpt.2667","article-title":"Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping","volume":"112","author":"White","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.118501_b0740","article-title":"Fluoropyrimidine Dosage and Toxicity","volume":"18","author":"Otero-Torres","year":"2025","journal-title":"An Umbrella Review of Systematic Reviews, Pharmaceuticals."},{"issue":"10","key":"10.1016\/j.bcp.2026.118501_b0745","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.apsb.2019.06.008","article-title":"Enhanced stability and efficacy of GEM-TOS prodrug by co-assembly with antimetastatic shell LMWH-TOS","volume":"10","author":"Guo","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"17","key":"10.1016\/j.bcp.2026.118501_b0750","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1002\/anie.201511808","article-title":"Membrane\u2010permeable triphosphate prodrugs of nucleoside analogues","volume":"55","author":"Gollnest","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"issue":"12","key":"10.1016\/j.bcp.2026.118501_b0755","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3390\/pharmaceutics16121549","article-title":"Innovative nanomedicine delivery: targeting tumor microenvironment to defeat drug resistance","volume":"16","author":"Meng","year":"2024","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.bcp.2026.118501_b0760","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1080\/17425247.2023.2292678","article-title":"Advancements in pH-responsive nanocarriers: enhancing drug delivery for tumor therapy","volume":"20","author":"Chen","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"issue":"10","key":"10.1016\/j.bcp.2026.118501_b0765","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody\u2013drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"12","key":"10.1016\/j.bcp.2026.118501_b0770","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf591","article-title":"Novel telomere-targeting dual-pharmacophore dinucleotide prodrugs for anticancer therapy","volume":"53","author":"Mender","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"44","key":"10.1016\/j.bcp.2026.118501_b0775","doi-asserted-by":"crossref","first-page":"38861","DOI":"10.1021\/acsnano.5c16609","article-title":"Chemotherapeutic Spherical Nucleic Acids","volume":"19","author":"Luo","year":"2025","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.bcp.2026.118501_b0780","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1016\/j.apsb.2025.05.008","article-title":"Design, synthesis, and antitumor activity of novel thioheterocyclic nucleoside derivatives by suppressing the c-MYC pathway","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2026.118501_b0785","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jconrel.2018.03.013","article-title":"N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer","volume":"277","author":"Chen","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118501_b0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118518","article-title":"CD123\/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape","volume":"568","author":"Sun","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bcp.2026.118501_b0795","doi-asserted-by":"crossref","DOI":"10.1201\/9780429065767","article-title":"Co-administration of iRGD enhances tumor-targeted delivery and anti-tumor effects of paclitaxel-loaded PLGA nanoparticles for colorectal cancer treatment","volume":"8543\u20138560","author":"Zhong","year":"2019","journal-title":"Int. J. Nanomedicine"},{"issue":"10","key":"10.1016\/j.bcp.2026.118501_b0800","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s44222-023-00082-0","article-title":"Self-assembled lipid\u2013prodrug nanoparticles","volume":"1","author":"Couvreur","year":"2023","journal-title":"Nat. Rev. Bioeng."},{"issue":"4","key":"10.1016\/j.bcp.2026.118501_b0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.109917","article-title":"Orally delivered berberine derivatives for dual therapy in diabetic complications with MRSA infections","volume":"36","author":"Gao","year":"2025","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.bcp.2026.118501_b0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.104872","article-title":"Gemcitabine and Pin1 siRNA co-delivery with fucoidan-coated nano-liposomes for therapy of pancreatic cancer","volume":"87","author":"Zheng","year":"2023","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0815","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12943-025-02325-7","article-title":"Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation","volume":"24","author":"Yi","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.118501_b0820","volume":"32","author":"Wang","year":"2025","journal-title":"Synergistic HER2-scFv Mediated Immunotherapy with Targeted Gemcitabine Delivery Harnessing Biomimetic Composite Nanoparticles for Enhanced Metastatic Tumor Therapy."},{"issue":"6","key":"10.1016\/j.bcp.2026.118501_b0825","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1016\/j.apsb.2023.03.004","article-title":"Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis","volume":"13","author":"Zhu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0830","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s12951-024-02745-5","article-title":"A bioinspired supramolecular nanoprodrug for precision therapy of B-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bcp.2026.118501_b0835","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcis.2016.10.041","article-title":"Nanoassemblies from amphiphilic cytarabine prodrug for leukemia targeted therapy","volume":"487","author":"Liu","year":"2017","journal-title":"J. Colloid Interface Sci."},{"issue":"8","key":"10.1016\/j.bcp.2026.118501_b0840","doi-asserted-by":"crossref","first-page":"7184","DOI":"10.1021\/acsnano.5c20618","article-title":"Collagenase-functionalized liposomes overcome stromal barriers in pancreatic cancer","volume":"20","author":"Hwang","year":"2026","journal-title":"ACS Nano"},{"issue":"38","key":"10.1016\/j.bcp.2026.118501_b0845","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202507118","article-title":"Cascade\u2010Targeted Nanoparticles for Enhanced Gemcitabine delivery and Adenosine Metabolism Modulation to Overcome Treatment Resistance in Pancreatic Cancer","volume":"12","author":"Fan","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bcp.2026.118501_b0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2022.104135","article-title":"FU-coating pH-sensitive liposomes for improving the release of gemcitabine by endosome escape in pancreatic cancer cells","volume":"80","author":"Li","year":"2023","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.bcp.2026.118501_b0855","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jconrel.2024.07.021","article-title":"Rational formulation and industrial manufacturing of lipid-based complex injectables: Landmarks and trends","volume":"373","author":"Biscaia-Caleiras","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2026.118501_b0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216166","article-title":"Barrier permeation and improved nanomedicine delivery in tumor microenvironments","volume":"562","author":"Liu","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2026.118501_b0865","article-title":"Supramolecular nanomedicine in the intelligent cancer therapy: recent advances and future","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"21","key":"10.1016\/j.bcp.2026.118501_b0870","first-page":"4815","volume":"80","author":"Zhao","year":"2020","journal-title":"5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers."},{"issue":"3","key":"10.1016\/j.bcp.2026.118501_b0875","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0242","article-title":"nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer","volume":"2","author":"Frese","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118501_b0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101395","article-title":"Reverse intratumor bacteria-induced gemcitabine resistance with carbon nanozymes for enhanced tumor catalytic-chemo therapy","volume":"43","author":"Xi","year":"2022","journal-title":"Nano Today"},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0885","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12935-023-03057-8","article-title":"Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia","volume":"23","author":"Bell","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2026.118501_b0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115389","article-title":"Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer","volume":"166","author":"Chen","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.bcp.2026.118501_b0895","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/1078-0432.CCR-22-2074","article-title":"A phase I\/II trial of oral SRA737 (a Chk1 Inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer","volume":"29","author":"Jones","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118501_b0900","article-title":"A polymeric nanovesicle delivers sulfopin and gemcitabine to remodel tumor microenvironment for enhanced chemoimmunotherapy against orthotopic pancreatic cancer","volume":"102153","author":"Jiang","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0905","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-020-01297-0","article-title":"Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma","volume":"20","author":"Guo","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0910","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12951-025-03335-9","article-title":"5-FU@ HFn combined with decitabine induces pyroptosis and enhances antitumor immunotherapy for chronic myeloid leukemia","volume":"23","author":"Yuan","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0915","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1021\/acsnano.2c07861","article-title":"Macrophage membrane-coated nano-gemcitabine promotes lymphocyte infiltration and synergizes AntiPD-L1 to restore the tumoricidal function","volume":"17","author":"Li","year":"2022","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.bcp.2026.118501_b0920","doi-asserted-by":"crossref","DOI":"10.1002\/smsc.202370023","article-title":"Targeting PD\u2010L1 with DNA Aptamers and Conjugated with Gemcitabine as a Novel Therapeutic Strategy for Bladder Cancer Chemotherapy combined with Immunotherapy","volume":"3","author":"Hu","year":"2023","journal-title":"Small Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.118501_b0925","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1021\/acs.jcim.3c00536","article-title":"Transformer-based Molecular Generative Model for Antiviral Drug Design","volume":"64","author":"Mao","year":"2024","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.bcp.2026.118501_b0930","doi-asserted-by":"crossref","first-page":"42295","DOI":"10.1038\/s41598-025-23435-8","article-title":"Transfer learning with multiomics integration and deep neural networks reveals drug resistance mechanisms in cancer","volume":"15","author":"Alpsoy","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118501_b0935","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1702720","article-title":"Clinical application and drug resistance mechanism of gemcitabine","volume":"13","author":"Zhang","year":"2025","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:20:53Z","timestamp":1791919253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":187,"alternative-id":["S0006295226008439"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118501","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleoside antitumor drugs: From molecular mechanisms and adaptive resistance to clinical translation","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118501","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118501"}}